SCHEMBL4818082

SCHEMBL4818082

CC1(C)CCN(C(=O)c2ccc3[nH]ccc3c2)C1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.54
FASN P49327 1/20 0.53
LMNA P02545 2/20 0.52
MAPT P10636 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
DRD2 P14416 1/20 0.50
DRD3 P35462 1/20 0.50
GPR183 P32249 1/20 0.50
HTR1A P08908 1/20 0.50
GHSR Q92847 1/20 0.47
MGLL Q99685 1/20 0.47
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
CHRNA7 P36544 1/20 0.46
NUDT15 Q9NV35 1/20 0.45
CYP2D6 P10635 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4818069 1.00 MAPK14 (0.54) MAPK14FASNLMNAMAPTL3MBTL1
SCHEMBL22216386 0.84 LMNA (0.56) MAPK14FASNLMNAMAPTL3MBTL1
SCHEMBL762616 0.82 MAPK14 (0.57) MAPK14FASNLMNAMAPTL3MBTL1
SCHEMBL30226931 0.80 MAPK14 (0.64) MAPK14FASNLMNADRD2DRD3
SCHEMBL22216445 0.80 MAPK14 (0.64) MAPK14FASNLMNAMAPTL3MBTL1
SCHEMBL8534513 0.80 MAPK14 (0.64) MAPK14FASNLMNADRD2DRD3
SCHEMBL30329646 0.80 MAPK14 (0.64) MAPK14FASNLMNAMAPTL3MBTL1
SCHEMBL3039407 0.80 MAPK14 (0.64) MAPK14FASNDRD2DRD3GPR183
SCHEMBL3457123 0.79 MAPK14 (0.63) MAPK14FASNLMNADRD2DRD3
SCHEMBL2214616 0.79 MAPK14 (0.63) MAPK14FASNLMNADRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402606-B2 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss SMITHKLINE BEECHAM CORPORATION (US) 2008-07-22 US claimed
EP-1494663-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SmithKline Beecham Corporation (US) 2005-01-12 EP claimed
WO-2003086385-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SMITHKLINE BEECHAM CORPORATION (US) 2003-10-23 WO claimed
US-7402606-B2 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss SMITHKLINE BEECHAM CORPORATION (US) 2008-07-22 US disclosed
EP-1494663-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SmithKline Beecham Corporation (US) 2005-01-12 EP disclosed
WO-2003086385-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SMITHKLINE BEECHAM CORPORATION (US) 2003-10-23 WO disclosed